1. Scrip
  2. >>Business
  3. >>Deals

Q1 Was Slow For Deals, But That Could Change With One Big Transaction – PwC

 
• By Joseph Haas

Life science deal-making declined by volume during the first quarter, but aggregate value was up. Looking ahead, PwC sees an ideal environment for major deals – if something like Takeda/Shire sparks a trend.

Rocket takes off from the hand of the businessman. Concept of start up.

By volume, life sciences deal-making declined during the first quarter of 2018, although four fairly large deals meant that the aggregate value of such deals rose compared to the fourth quarter, PwC’s deal practice notes in a new report. But the group thinks completion of one big transaction could open the floodgates, so to speak.

There has been a lot of speculation about an increase in deals with the US corporate tax reform that passed late last year, and Takeda Pharmaceutical Co. Ltd.’s pursuit of Shire PLC – currently valued at about $64.3bn, which would make it one of the largest biopharma deals ever – shows that mega-mergers are back on the table

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

More from Business

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.